KAEL-GemVax Co., Ltd.
π°π·South Korea
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)β’ Click on a phase to view related trials
Phase 2
1 (50.0%)Phase 3
1 (50.0%)Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer
Phase 3
- Conditions
- Inoperable Stage III Non-small Cell Lung Cancer
- Interventions
- Drug: normal saline
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Kael-GemVax Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT01579188
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
Phase 2
- Conditions
- Prostate Cancer
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- Kael-GemVax Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT00514072
- Locations
- πΊπΈ
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
News
No news found